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Background: Galectin-3 is a prognostic heart failure (HF) biomarker that may mediate cardiac fibrosis.
methods: 151 subjects with left ventricular systolic dysfunction (LVSD) were followed through 908 visits over 10 ± 3 months. Time spent relative to 
a galectin-3 level ≤20.0 ng/mL was considered across study visits, and used to assess risk for adverse cardiovascular (CV) events and associations 
with LV remodeling. Medication effects on galectin-3 were examined.
results: Median galectin-3 values at baseline, 3 months, and 6 months were higher in patients with CV events (21.7 vs. 18.4 ng/mL, p = 0.03; 
21.7 vs. 16.5 ng/mL, p = 0.03; 23.2 vs. 16.0 ng/mL, p = 0.007). Galectin-3 concentration changed in 35.2% of subjects during study procedures. 
Duration of time spent ≤20.0 ng/mL was significantly associated with a lower rate of CV events (Figure), independently predicted CV events even 
when adjusted for relevant variables including NT-proBNP and renal function (OR = 0.90; 95% confidence interval [CI] = 0.82-0.99, p = 0.04), and 
was predictive of increase in LV ejection fraction (OR = 1.20; 95% CI = 1.01-1.42, p = 0.04). Serial galectin-3 measurement at 6 months added 
prognostic value beyond baseline level (p = 0.02), and increases in loop diuretics were associated with galectin-3 increase (p = 0.01).
conclusions: In chronic HF due to LVSD, serial galectin-3 measurement adds incremental prognostic information and predicts LV remodeling. In 
this study, most HF therapies did not significantly change galectin-3 levels.
 
